Kiniksa Pharmaceuticals International (KNSA) Long-Term Deferred Tax (2017 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has 9 years of Long-Term Deferred Tax data on file, last reported at $191.0 million in Q2 2026.

• Quarterly Long-Term Deferred Tax fell 7.08% year-over-year to $191.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $191.0 million (down 7.08% YoY) and the FY2025 annual result came in at $198.1 million, down 6.16% from the prior year.
• Long-Term Deferred Tax slipped to $191.0 million in Q2 2026, from $193.6 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $219.3 million in Q4 2023 to a low of $184.4 million in Q1 2023.
• A 5-year average of $200.5 million and a median of $202.6 million in 2023 frame the typical range for Long-Term Deferred Tax.
• Annual changes were most pronounced in 2023 — Long-Term Deferred Tax increased 18.22% — and 2026, when it dropped 7.08%.
• Tracing KNSA's Long-Term Deferred Tax over 5 years: stood at $185.5 million in 2022, then climbed by 18.22% to $219.3 million in 2023, then declined by 3.71% to $211.2 million in 2024, then decreased by 6.16% to $198.1 million in 2025, then dropped by 3.63% to $191.0 million in 2026.
• The last three Long-Term Deferred Tax figures came in at $191.0 million (Q2 2026), $193.6 million (Q1 2026), and $198.1 million (Q4 2025), per Business Quant data.